...
首页> 外文期刊>Food and Chemical Toxicology: An International Journal Published for the British Industrial Biological Research >Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)on-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1
【24h】

Amelioration by chicory seed extract of diabetes- and oleic acid-induced non-alcoholic fatty liver disease (NAFLD)on-alcoholic steatohepatitis (NASH) via modulation of PPARα and SREBP-1

机译:菊苣种子提取物通过调节PPARα和SREBP-1改善糖尿病和油酸诱导的非酒精性脂肪肝病(NAFLD)/非酒精性脂肪性肝炎(NASH)

获取原文
获取原文并翻译 | 示例
           

摘要

We evaluated the effect of chicory (Cichorium intybus L.) seed extract (CI) on hepatic steatosis caused by early and late stage diabetes in rats (in vivo), and induced in HepG2 cells (in vitro) by BSA-oleic acid complex (OA). Different dosages of CI (1.25, 2.5 and 5. mg/ml) were applied along with OA (1. mM) to HepG2 cells, simultaneously and non-simultaneously; and without OA to ordinary non-steatotic cells. Cellular lipid accumulation and glycerol release, and hepatic triglyceride (TG) content were measured. The expression levels of sterol regulatory element-binding protein-1c (SREBP-1c) and peroxisome proliferator-activated receptor alpha (PPARα) were determined. Liver samples were stained with hematoxylin and eosin (H&E). Significant histological damage (steatosis-inflammation-fibrosis) to the cells and tissues and down-regulation of SREBP-1c and PPARα genes that followed steatosis induction were prevented by CI in simultaneous treatment. In non-simultaneous treatment, CI up-regulated the expression of both genes and restored the normal levels of the corresponding proteins; with a greater stimulating effect on PPARα, CI acted as a PPARα agonist. CI released glycerol from HepG2 cells, and targeted the first and the second hit phases of hepatic steatosis. A preliminary attempt to characterize CI showed caffeic acid, chlorogenic acid, and chicoric acid, among the constituents.
机译:我们评估菊苣(菊苣(Cichorium intybus L.)种子提取物(CI)对大鼠(体内)早期和晚期糖尿病引起的肝脂肪变性的影响,并通过BSA-油酸复合物(体外)在HepG2细胞中诱导(体外)。 OA)。将不同剂量的CI(1.25、2.5和5. mg / ml)与OA(1.mM)一起同时而非同时地应用于HepG2细胞;对普通的非脂肪细胞没有OA。测量细胞脂质积累和甘油释放,以及肝甘油三酯(TG)含量。测定了固醇调节元件结合蛋白1c(SREBP-1c)和过氧化物酶体增殖物激活受体α(PPARα)的表达水平。肝样品用苏木精和曙红(H&E)染色。在同时治疗中,CI可防止对细胞和组织的明显组织学损伤(硬脂化-炎症-纤维化)以及在脂肪变性诱导后SREBP-1c和PPARα基因的下调。在非同时治疗中,CI上调了两个基因的表达并恢复了相应蛋白质的正常水平。 CI对PPARα的刺激作用更大,CI充当PPARα激动剂。 CI从HepG2细胞释放甘油,并靶向肝脂肪变性的第一个和第二个击中阶段。初步表征CI的方法是在成分中加入咖啡酸,绿原酸和Chicoric酸。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号